Market capitalization | $120.73m |
Enterprise Value | $157.83m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 13.83 |
EV/Sales (TTM) EV/Sales | 1.48 |
P/S ratio (TTM) P/S ratio | 1.13 |
P/B ratio (TTM) P/B ratio | 1.75 |
Sales growth (TTM) Sales growth | -6.76% |
Turnover (TTM) Turnover | $106.79m |
As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.
2 Analysts have issued a Harvard Bioscience, Inc. forecast:
2 Analysts have issued a Harvard Bioscience, Inc. forecast:
Dec '23 |
+/-
%
|
||
Net profit | -3.42 -3.42 |
64%
64%
|
|
Depreciation and amortization | 7 7 |
8%
8%
|
|
Share compensation | 5 5 |
13%
13%
|
|
Operating cash flow | 14 14 |
1,120%
1,120%
|
|
Investments | 2.31 2.31 |
45%
45%
|
|
Dividend paid | - - |
-
|
|
Free cash flow | 12 12 |
2,882%
2,882%
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. It operates under the geographical segments: United States, Germany, United Kingdom, and Rest of the world. It sells its products through catalog, Website, distributors, and direct sales force. The company was founded by Dr. William T. Porter in 1901 and is headquartered in Holliston, MA.
Head office | United States |
CEO | James Green |
Employees | 416 |
Founded | 1901 |
Website | www.harvardbioscience.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.